Page last updated: 2024-12-04

4-aminoimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-aminoimidazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-aminoimidazole : An aminoimidazole that is 1H-imidazole substituted by an amino group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID484
CHEBI ID16607
MeSH IDM0258321

Synonyms (31)

Synonym
BB 0262079
1h-imidazol-4-amine
CHEBI:16607
4-(or 5-)aminoimidazole
4919-03-3
C05239
4-aminoimidazole
5-aminoimidazole
FT-0650211
1h-imidazol-5-amine
AKOS005259860
AKOS006282285
unii-7854bcq2ps
7854bcq2ps ,
MB08721
QRZMXADUXZADTF-UHFFFAOYSA-N
1,3-diazolium-4-aminide
DTXSID00197702
1h-imidazol-4-ylamine
3h-imidazol-4-amine
BCP05277
mfcd10697825
SY013999
mfcd00235200
Q27101994
AMY40030
P20245
AS-56807
A853362
EN300-177717
imidazole, 4-amino-

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"We aimed to study the effects of free fatty acids (FFAs) alone and combined with the exercise mimetics adrenaline and 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) in the production of IL6, IL15 and Irisin in muscle cells, using a time-sequential model."( Free fatty acid effects on myokine production in combination with exercise mimetics.
Nozhenko, Y; Palou, A; Rodríguez, AM; Sánchez, J, 2013
)
0.39
"To study the effect of 5-aminoimidazole-4-formamide ribonucleotide (AICAR) combined with interferon (IFN-α-2b) on the proliferation and apoptosis of chronic myeloid leukemia K562 cells, and explore its possible mechanism."( [Effect of 5-aminoimidazole-4-formamide Ribonucleotide Combined with Interferon on Chronic Myeloid Leukemia K562 Cells].
Ge, FM; Liu, R; Wang, HJ; Zhang, YY, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoimidazoleAny member of the class of imidazoles carrying at least one amino substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
purine nucleobases degradation I (anaerobic)240
purine nucleobases degradation II (anaerobic)051

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (31.25)18.7374
1990's1 (3.13)18.2507
2000's1 (3.13)29.6817
2010's10 (31.25)24.3611
2020's10 (31.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.49 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.13%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]